# Energy expenditure and cellular activity underlie antibiotic tolerance of Pseudomonas aeruginosa

**Authors:** Michael F. Gates, Kim Lewis

PMC · DOI: 10.1128/mbio.03968-25 · 2026-02-19

## TL;DR

This paper explains how Pseudomonas aeruginosa becomes antibiotic-tolerant in cystic fibrosis infections by linking energy use and cellular activity to the formation of dormant persister cells.

## Contribution

The study reveals that high energy expenditure and biofilm lifestyle in Pseudomonas aeruginosa lead to antibiotic tolerance via low-translating persister cells.

## Key findings

- Pseudomonas aeruginosa remains highly active in stationary phase, leading to increased antibiotic susceptibility compared to Escherichia coli.
- Low-translating persisters in Pseudomonas aeruginosa arise under high c-di-GMP production and intact exopolysaccharide synthesis.
- Biofilm growth increases antibiotic tolerance by generating dormant persisters with reduced energy expenditure.

## Abstract

Persisters are a subpopulation of bacterial cells that survive a lethal dose of antibiotic. The failure to treat infections has been linked to the presence of these drug-tolerant cells. The recalcitrant, and often incurable, infection of cystic fibrosis airways by Pseudomonas aeruginosa is attributed to persisters found within aggregate biofilms that contain stationary cells. In all bacteria studied, the fraction of persisters is the highest in stationary populations. However, the level of persisters is unusually low in stationary phase P. aeruginosa, which is unexpected, given the recalcitrance to antibiotic therapy. Here, we set out to investigate the mechanism of P. aeruginosa antibiotic susceptibility in stationary phase. We find that P. aeruginosa is highly active in stationary phase, based on its rate of translation, and this correlates with increased killing compared to Escherichia coli. Growth within alginate beads improves P. aeruginosa stationary cell tolerance to antibiotic treatment, likely due to a subpopulation of low-translating cells. Secondary messenger cyclic diguanylate (c-di-GMP) regulates biofilm formation, and we find that a population of low-translating persisters also appeared in planktonically growing cells when c-di-GMP production is induced. This phenotype only occurred when exopolysaccharide production was intact, and we propose that the energetic demand of EPS overproduction induces dormancy. The level of energy expenditure appears to determine persistence in P. aeruginosa. In vivo-like growth conditions and a shift to a biofilm lifestyle, mediated by high c-di-GMP production, increase antibiotic tolerance by generating low-energy, dormant persisters.

Recalcitrant bacterial infections are a continued burden on the healthcare system. Antibiotic treatment failure, especially for chronic infections, can be attributed to persisters, a subpopulation of dormant cells that survive a lethal dose of drug. The infection of cystic fibrosis (CF) airways by Pseudomonas aeruginosa is often incurable to treatment by multiple classes of antibiotics due to the presence of persisters. P. aeruginosa, however, is highly susceptible to antibiotic killing in vitro, in apparent contradiction of its drug tolerance during infection. Here, we show that P. aeruginosa susceptibility to antibiotic killing is due to its continued protein synthesis and cellular activity even with entrance into stationary phase. Furthermore, we identify that the greater energetic demand of biofilm growth generates a larger fraction of low-translating persisters and increases antibiotic tolerance. These findings improve our understanding of P. aeruginosa antibiotic tolerance during CF infection and will aid the development of better treatment regimens.

## Linked entities

- **Diseases:** cystic fibrosis (MONDO:0009061)
- **Species:** Pseudomonas aeruginosa (taxon 287), Escherichia coli (taxon 562)

## Full-text entities

- **Genes:** phosphodiesterase [NCBI Gene 9538128]
- **Diseases:** urinary tract infection (MESH:D014552), infection (MESH:D007239), bacterial infections (MESH:D001424), CF (MESH:D003550)
- **Chemicals:** fluoroquinolone (MESH:D024841), c-di-GMP (MESH:C062025), pyoverdine (MESH:C042453), MgSO4 (MESH:D008278), proton (MESH:D011522), DS (-), formaldehyde (MESH:D005557), PDE (MESH:C048587), glucose (MESH:D005947), L-threonine (MESH:D013912), M8 (MESH:C017233), beta-lactams (MESH:D047090), sucrose (MESH:D013395), purine (MESH:C030985), arabinose (MESH:D001089), Na2CO3 (MESH:C005686), ATP (MESH:D000255), citric acid (MESH:D019343), ciprofloxacin (MESH:D002939), casamino acids (MESH:C017721), Triton X-100 (MESH:D017830), agar (MESH:D000362), acid (MESH:D000143), Nitrate (MESH:D009566), aminoglycoside (MESH:D000617), Alginate (MESH:D000464), EPS (MESH:C100219), NaCl (MESH:D012965), pyrimidine (MESH:C030986), carbenicillin (MESH:D002228), Tobramycin (MESH:D014031), CaCl2 (MESH:D002122), gentamicin (MESH:D005839), water (MESH:D014867)
- **Species:** Caulobacter vibrioides (species) [taxon 155892], Homo sapiens (human, species) [taxon 9606], Staphylococcus aureus (species) [taxon 1280], Mycobacterium tuberculosis (species) [taxon 1773], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Escherichia coli str. K-12 substr. MG1655 (no rank) [taxon 511145], Pseudomonas aeruginosa (species) [taxon 287], Escherichia coli (E. coli, species) [taxon 562], aureus [taxon 46170], Salmonella enterica subsp. enterica serovar Typhimurium (no rank) [taxon 90371], Pseudomonas aeruginosa PAO1 (strain) [taxon 208964], Salmonella enterica (species) [taxon 28901]
- **Cell lines:** MG1655 — Homo sapiens (Human), Maple syrup urine disease, Transformed cell line (CVCL_D514), PAO1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), S2 — Drosophila melanogaster (Fruit fly), Spontaneously immortalized cell line (CVCL_Z232)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12977519/full.md

---
Source: https://tomesphere.com/paper/PMC12977519